. Author manuscript; available in PMC: 2014 Mar 1.

Published in final edited form as: Headache. 2013 Mar;53(3):474–490. doi: 10.1111/head.12071

Table 5.

Adjusted^ŧ Adiponectin Ratios in Women Episodic Migraine Responders and Non-Responders Before and After Treatment

		HMW : T-ADP			LMW : T-ADP			LMW : T-ADP
		Coefficient (SE)	95% CI	p-value	Coefficient (SE)	95% CI	p-value	Coefficient (SE)	95% CI	p-value
Responders	Time-Point
	T0 (Onset)	Reference			Reference			Reference
	30 min	−0.02 (0.02)	−0.06, 0.02	0.33	0.48 (0.45)	−1.37, 0.41	0.29	0.03 (0.02)	−0.02, 0.08	0.22
	60 min	−0.05 (0.020)	−0.09, −0.01	0.02	−1.34 (0.45)	−2.23, −0.45	0.003	0.06 (0.02)	0.02, 0.11	0.008
	120 min	−0.05 (0.02)	−0.09, −0.01	0.02	−0.94 (0.45)	−1.83, −0.05	0.04	0.03 (0.02)	−0.01, 0.08	0.14
		HMW : T−ADP			LMW : T−ADP			LMW : T−ADP
		Coefficient (SE)	95% CI	p−value	Coefficient (SE)	95% CI	p−value	Coefficient (SE)	95% CI	p−value
Non-Responders	Time-Point
	T0 (Onset)	Reference			Reference			Reference
	30 min	0.02 (0.03)	−0.03, 0.07	0.396	0.85 (0.86)	−0.85, 2.54	0.327	−0.02 (0.03)	−0.08, 0.03	0.434
	60 min	0.02 (0.03)	−0.03, 0.07	0.485	1.10 (0.86)	−0.59, 2.79	0.204	−0.04 (0.03)	−0.09, 0.02	0.188
	120 min	0.04 (0.03)	−0.008, 0.092	0.096	1.93 (0.86)	0.24, 3.62	0.025	−0.03 (0.03)	−0.08, 0.02	0.284

Table 4: Mean adjusted change in adiponectin (ADP) ratio levels in episodic women migraineurs after treatment, stratified by response. HMW:LMW ADP levels were decreased in responders and increased in non-responders after adjustments. All p-values are comparisons to T0. T0=pain onset;

^ŧ

Results adjusted for BMI, age, race, and study site. Among responders, no participants were enrolled from the DM site and thus omitted from the model. Among non-responders, JH participants were dropped due to colinearity with the outcome.

CI=confidence interval; SE=standard error; HMW-ADP=high molecular weight adiponectin; MMW-ADP=middle molecular weight adiponectin; LMW-ADP=low molecular weight adiponectin